Genovis AB (publ.) (GENO)
Free
No email, no account, no signup.
Pulling latest news for Genovis AB (publ.)…
Bull
Bear
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99.
Get the deep 4-model report – $4.99
Signal
NEUTRAL
Sentiment
7/10
Risk
4/10
Get full analysis with Bull/Bear case, catalysts, and risk analysis
Order analysis – $4.99
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Genovis AB (publ.) develops and sells enzyme-based tools ("SmartEnzymes") used in development and quality control of biologic drugs. The company is profitable with high gross margins and expanded its portfolio via Sequrna (RNase inhibitors) targeting RNA/NGS workflows.
Exchange
Nasdaq First North Growth Market
Type
Biotech
Sector
Life science tools and enzyme technology
Market Cap
$110M
Market sentiment
Sentiment appears neutral-to-positive and improving, driven by orders/partnerships and portfolio expansion. Ongoing concerns include FX effects and quarterly revenue lumpiness.
Why NEUTRAL ?
- **Review/wait** for Q1 2026 to assess actual growth, margins, and integration impact
- **Positive**: profitability and strong cash reduce financing risk
- **Uncertainty**: speed of monetization from new deals/Sequrna and how much is already priced in
- Hold existing position; consider adding after a strong Q1 report.
Recent News
- Since 2026-04-06: AGM notice published (2026-04-15; AGM on 2026-05-18), 2025 annual report published (2026-04-23), and Q1 2026 interim report released (2026-04-28). Q1: net sales 33.5 MSEK (32.3), +4% reported but +17% FX-adjusted; negative FX impact about -4 MSEK. EBITDA 9.5 MSEK (28.4% margin), EBIT 5.8 MSEK (17.2% margin), net profit 4.3 MSEK, EPS 0.06 SEK. Operating cash flow 16.5 MSEK and cash 170.9 MSEK. Report-day share reaction about -3.4% per compiled research. Some target price tweaks (SEB up, Nordea slightly down) with Buy ratings reiterated per compiled research.
Bull case
- **Q1 report (28 Apr 2026)** may confirm continued growth and margin strength
- **Delivery/impact of a larger order (~EUR 1m)** could support revenue/cash flow in early 2026
- **News momentum** from partnerships/licensing may support valuation
Unlock to read more →
Bear case
- **FX headwinds (strong SEK)** can pressure reported revenue
- **Timing risk**: partnerships/licensing may have limited Q1 financial impact
- **Quarterly lumpiness** in orders can lead to disappointment
Unlock to read more →
Catalysts
18 May 2026 — AGM 2026
Dilution Risk
Assessment: Low
Order analysis – $4.99
Save hours of research. $4.99.
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Want to read the full analysis?
Order a fresh analysis of Genovis AB (publ.) – ready in your inbox in 5–15 minutes.
- Signal + risk + sentiment
- Bull/Bear case + triggers
- Catalysts with dates
- Saved as a webpage in your account
- Ready in 5–15 min (email when ready)
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Fact-based analysis
Updated weekly
No commitment period
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.